ClinicalTrials.gov
ClinicalTrials.gov Menu

FAST GFR: Pilot Study to Evaluate the Safety of the FAST GFR Test in Patients.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01978314
Recruitment Status : Completed
First Posted : November 7, 2013
Results First Posted : December 12, 2017
Last Update Posted : December 12, 2017
Sponsor:
Collaborators:
National Institutes of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Information provided by (Responsible Party):
FAST BioMedical

Brief Summary:
This is a single site study designed to evaluate the FAST mGFR Test™ in healthy adult volunteers, patients with varying degrees of chronic kidney disease (CKD), and patients with acute kidney injury (AKI).

Condition or disease Intervention/treatment Phase
Chronic Kidney Disease Acute Kidney Injury Device: 75 mg / 6 mL VFI™ Not Applicable

Detailed Description:
A rapid and accurate measurement of glomerular filtration rate (GFR) is important in acute kidney injury (AKI) and chronic kidney disease (CKD) for assessment of impairment, diagnosis, and prompt treatment. FAST BioMedical is an emerging technology company whose mission is to quantify clinically meaning ful physiological parameters that have been difficult or impossible to measure. GFR is the most clinically relevant metric for understanding renal function, as it is the rate by which the kidney is able to filter waste products in the bloodstream. The FAST mGFR is for direct measurement of GFR that relies on reading the ratio of fluorescent markers attached to different size dextran molecules introduced into the bloodstream. The test is intended as an adjunct to current methods utilized to assess kidney function.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 33 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: This pilot study was a prospective, open-label, single site study designed to evaluate the safety of the FAST mGFR Test™ in healthy adult volunteers, patients with varying degrees of renal impairment and hemodynamically stable AKI.
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: A Single-Center Prospective Study Evaluating the FAST Measured Glomerular Filtration Rate (mGFR) Test™ in Adults With Preserved Kidney Function and Impaired Kidney Function With Comparison to Iohexol Clearance Methods
Study Start Date : August 2013
Actual Primary Completion Date : August 2014
Actual Study Completion Date : August 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Kidney Diseases
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Cohort 1
eGFR renal function ≥60 mL/min for normal function 75 mg / 6mL VFI™ and 5mL of Iohexol
Device: 75 mg / 6 mL VFI™
Visible fluorescent injectate, a mixture of two different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.
Experimental: Cohort 2
eGFR renal function 30-59 mL/min for stage 3, moderate CKD 75 mg / 6mL VFI™ and 5mL of Iohexol
Device: 75 mg / 6 mL VFI™
Visible fluorescent injectate, a mixture of two different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.
Experimental: Cohort 3
eGFR renal function 15-29 mL/min for stage 4, severe CKD 75 mg / 6mL VFI™ and 5mL of Iohexol
Device: 75 mg / 6 mL VFI™
Visible fluorescent injectate, a mixture of two different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.
Experimental: Cohort 4
a diagnosis of either RIFLE stage I or Acute Kidney Injury Network (AKIN) stage 2 AKI 75 mg / 6mL VFI™ and 5mL of Iohexol
Device: 75 mg / 6 mL VFI™
Visible fluorescent injectate, a mixture of two different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.
Experimental: Cohort 5
eGFR renal function ≥60 mL/min for normal function 75 mg / 6mL VFI™ and 5mL of Iohexol
Device: 75 mg / 6 mL VFI™
Visible fluorescent injectate, a mixture of two different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.



Primary Outcome Measures :
  1. Number of Subjects With Adverse Events Following Administration of VFI™ in Patients With Varying Degrees of Kidney Function [ Time Frame: Baseline through day 22 ]
    An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product or investigational medical device.

  2. Number of Adverse Events Following Administration of VFI™ in Patients With Varying Degrees of Kidney Function [ Time Frame: Baseline through day 22 ]
    An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product or investigational medical device.


Secondary Outcome Measures :
  1. Cmax of FD001 and FD003 Following Administration of VFI™ in Patients With Varying Degrees of Kidney Function [ Time Frame: PK parameters were evaluated using samples collected pre and post dose at day 2, as well as post dose on days 4, 8, 15, 22. ]
    Cmax = maximum observed concentration occurring at Tmax

  2. Tmax of FD001 and FD003 Following Administration of VFI™ in Patients With Varying Degrees of Kidney Function [ Time Frame: PK parameters were evaluated using samples collected pre and post dose at day 2, as well as post dose on days 4, 8, 15, 22. ]
    Tmax = time of maximum observed concentration

  3. AUClast of FD001 and FD003 Following Administration of VFI™ in Patients With Varying Degrees of Kidney Function [ Time Frame: PK parameters were evaluated using samples collected pre and post dose at day 2, as well as post dose on days 4, 8, 15, 22. ]
    AUClast = area under the concentration-time curve (time 0 to last sample with a quantifiable measurable concentration)

  4. AUCall of FD001 and FD003 Following Administration of VFI™ in Patients With Varying Degrees of Kidney Function [ Time Frame: PK parameters were evaluated using samples collected pre and post dose at day 2, as well as post dose on days 4, 8, 15, 22. ]
    AUCall = area under the concentration-time curve (time 0 to last scheduled sample)

  5. AUCinf of FD001 and FD003 Following Administration of VFI™ in Patients With Varying Degrees of Kidney Function [ Time Frame: PK parameters were evaluated using samples collected pre and post dose at day 2, as well as post dose on days 4, 8, 15, 22. ]
    AUCinf = area under the concentration-time curve (time 0 extrapolated to infinity based on the last observed concentration)

  6. T1/2, z of FD001 and FD003 Following Administration of VFI™ in Patients With Varying Degrees of Kidney Function [ Time Frame: PK parameters were evaluated using samples collected pre and post dose at day 2, as well as post dose on days 4, 8, 15, 22. ]
    T1/2 = terminal half-life = ln(2)/λz

  7. Vz of FD001 and FD003 Following Administration of VFI™ in Patients With Varying Degrees of Kidney Function [ Time Frame: PK parameters were evaluated using samples collected pre and post dose at day 2, as well as post dose on days 4, 8, 15, 22. ]
    Vz = volume of distribution based upon terminal phase

  8. Vss of FD001 and FD003 Following Administration of VFI™ in Patients With Varying Degrees of Kidney Function [ Time Frame: PK parameters were evaluated using samples collected pre and post dose at day 2, as well as post dose on days 4, 8, 15, 22. ]
    Vss = volume of distribution at steady state

  9. CL of FD001 and FD003 Following Administration of VFI™ in Patients With Varying Degrees of Kidney Function [ Time Frame: PK parameters were evaluated using samples collected pre and post dose at day 2, as well as post dose on days 4, 8, 15, 22. ]
    CL = total body clearance

  10. Cmax/Dose of FD001 and FD003 Following Administration of VFI™ in Patients With Varying Degrees of Kidney Function [ Time Frame: PK parameters were evaluated using samples collected pre and post dose at day 2, as well as post dose on days 4, 8, 15, 22. ]
    Cmax/Dose = maximum observed concentration occurring at Tmax/Dose

  11. AUCinf/Dose of FD001 and FD003 Following Administration of VFI™ in Patients With Varying Degrees of Kidney Function [ Time Frame: PK parameters were evaluated using samples collected pre and post dose at day 2, as well as post dose on days 4, 8, 15, 22. ]
    AUCinf/Dose = area under the concentration-time curve (time 0 extrapolated to infinity based on the last observed concentration)/Dose

  12. To Compare the Results From the GFR Determined From the FAST VFI™ to GFR Derived From Iohexol Clearance Methods. [ Time Frame: Baseline through Day 22 ]
    This analysis will compare estimates of kidney function derived from the results of FAST VFI™ to those derived through conventional Iohexol clearance methods.

  13. To Evaluate the Correlation Between FAST's Plasma Volume Method and Standard Clinical Estimates of Plasma Volume. [ Time Frame: Baseline through day 22 ]
    This analysis will compare estimates of plasma volume derived by FAST's plasma volume method with that derived using the conventional Nadler's Formula for plasma volume.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   19 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria for Groups 1-3:

  • Female subjects: women must have a negative urine pregnancy test at screening and before dosing on Visit 2 and be either confirmed by the Investigator to be infertile or using a reliable method of contraception Male subjects: reproductively active men must agree to either practice abstinence or utilize adequate contraception.
  • Ages 19 to 75
  • Subject's screening must fall into one of the available categories of estimated glomerular filtration rate (eGFR) renal function: ≥ 60 mL/min for stage normal function; 30-59 mL/min for stage 3, moderate CKD; 15-29 mL/min for stage 4, severe CKD,
  • Patients must not be on inotropes or vasopressors, and must be absent of significant hemodynamic instabilities.
  • Patients must have ceased use of the following:

    • nonsteroidal anti-inflammatory drugs - 6 days prior,
    • herbal supplements - 6 days prior to testing and
    • cimetidine and trimethoprim - 14 days prior to testing.
  • Ability to comply with study conditions

Inclusion Criteria for Group 4:

- Female subjects; women must have a negative urine pregnancy test at screening and before dosing on Visit 2 and be either confirmed by the Investigator to be infertile or using a reliable method of contraception.

Male subjects: reproductively active men must agree to either practice abstinence or utilize adequate contraception.

  • Ages 19 to 75
  • For cohort 4: patients diagnosed with [either RIFLE stage I or Acute Kidney Injury Network (AKIN) stage 2 AKI]
  • Patients must not be on inotropes or vasopressors, and must be absent of significant hemodynamic instabilities.
  • Patients must be without evidence of clinically significant liver dysfunction
  • Ability to comply with study conditions

Exclusion Criteria for Groups 1-3:

  • Positive history of any clinically significant allergic or negative reactions, side effects, or anaphylaxis to sulfa, iodine, dyes, shellfish, isotopes or dextran molecules
  • Previous history of nephrectomy or kidney transplant
  • A body weight below 40kg
  • A body mass index <17 or >40
  • Subjects using Coumadin (Warfarin) who have an INR >4 at Screening or pre-dose on Visit 2
  • Past history of liver disease or screening Liver Function tests which exceed 1.5 times the upper limit of normal or an albumin of < 2mg/dl.
  • Clinically significant illness within 4 weeks or a clinically significant infection within 4 weeks of screening
  • Received blood, donated blood, have clinically significant on-going bleeding, changing haemoglobin, or experienced significant blood loss within 2 weeks of dosing
  • Subjects with significant abnormal findings upon physical examination, vital signs, ECG, or clinical laboratory results at Screening
  • Subjects with a supine blood pressure after resting for at least 5 minutes outside the 90-145 (systolic) or mmHg or 50-95 mmHg (diastolic) range
  • Subjects with a supine (ECG) heart rate outside 45-105 beats/min after resting for at least 5 minutes.
  • Subjects with a known or suspected history of drug or alcohol misuse within 6 months prior to screening, subjects who have consumed alcohol within 48 hours of dosing, or subjects who the Investigator believes to be unfit to participate in the study due to abuse of illegal or controlled substances.
  • Subjects who had a positive result for Hepatitis B surface antigen (HBsAg) or Hepatitis C virus antibody (HCVAb) screen.
  • Subjects who have been diagnosed with acquired immune deficiency syndrome (AIDS), or test positive for human immunodeficiency virus (HIV).
  • Subjects who participated in another clinical trial less than 1 month prior to dosing, or who are currently enrolled in another clinical trial.
  • Subjects who have any condition that:

    • Would make him/her, in the opinion of the Investigator, unsuitable for the study
    • Whose condition is likely to deteriorate
    • Who, in the opinion of the Investigator, is not likely to complete the study for any reason

Exclusion Criteria for Group 4:

  • Positive history of any clinically significant allergic or negative reactions, side effects, or anaphylaxis to sulfa, iodine, dyes, shellfish, isotopes or dextran molecules
  • Previous history of nephrectomy or kidney transplant
  • A body weight below 40kg
  • A body mass index <17 or >40
  • Current use of prescribed anticoagulants
  • Past history of liver disease or screening Liver Function tests which exceed 1.5 times the upper limit of normal or an albumin of < 2mg/dl.
  • Received blood, donated blood, have clinically significant on-going bleeding, changing haemoglobin, or experienced significant blood loss within 2 weeks of dosing
  • Subjects with a supine blood pressure after resting for at least 5 minutes outside the 90-145 (systolic) or mmHg or 50-95 mmHg (diastolic) range
  • Subjects with a supine (ECG) heart rate outside 45-105 beats/min after resting for at least 5 minutes.
  • Subjects with a known or suspected history of drug or alcohol abuse within 6 months prior to admission, who have a positive drug test or alcohol test, or who have consumed alcohol within 24 of testing
  • Subjects who had a positive result for Hepatitis B surface antigen (HBsAg) or Hepatitis C virus antibody (HCVAb) screen.
  • Subjects who have been diagnosed with acquired immune deficiency syndrome (AIDS), or test positive for human immunodeficiency virus (HIV).
  • Subjects who participated in another clinical trial less than 1 month prior to dosing, or who are currently enrolled in another clinical trial.
  • Subjects who have any condition that:

    • Would make him/her, in the opinion of the Investigator, unsuitable for the study
    • Whose condition is likely to deteriorate
    • Who, in the opinion of the Investigator, is not likely to complete the study for any reason

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01978314


Locations
United States, Alabama
University of Alabama Birmingham, Division of Nephrology
Birmingham, Alabama, United States, 35294-0007
Sponsors and Collaborators
FAST BioMedical
National Institutes of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Investigators
Principal Investigator: Dana V Rizk, M.D University of Alabama Birmingham, 205-934-9509, drizk@uab.edu

Publications:
Responsible Party: FAST BioMedical
ClinicalTrials.gov Identifier: NCT01978314     History of Changes
Other Study ID Numbers: FAST mGFR -002
1R44DK093274-01 ( U.S. NIH Grant/Contract )
First Posted: November 7, 2013    Key Record Dates
Results First Posted: December 12, 2017
Last Update Posted: December 12, 2017
Last Verified: November 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Keywords provided by FAST BioMedical:
Chronic Kidney Disease
Acute Kidney Injury
AKI
CKD
Plasma Volume
GFR
Glomerular Filtration Rate
Blood volume
mGFR
measured GFR
kidney biomarker
renal disease
renal biomarker
Renal function
kidney function
organ function
kidney monitor
kidney device

Additional relevant MeSH terms:
Kidney Diseases
Renal Insufficiency, Chronic
Acute Kidney Injury
Urologic Diseases
Renal Insufficiency